Travere Therapeutic

Recent news

• Rating change
  Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $78
  Market Newswire · 2026/8/10
• Rating change
  CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $62
  Market Newswire · 2026/7/30
• Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $89
  Market Newswire · 2026/9/24
• Rating change
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $70 to $90
  Market Newswire · 2026/8/7
• Rating change
  Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $61
  Market Newswire · 2026/7/13
• Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $76
  Market Newswire · 2026/9/22
• Travere Therapeutics: Eric Dube, Ph.D., to Step Down as Pres and CEO in Dec TVTX
  Dow Jones · 2026/9/22
• Rating change
  J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $90
  Market Newswire · 2026/8/7
• Rating change
  TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2026/7/22
• Rating change
  Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $68
  Market Newswire · 2026/8/17
• BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $71
  Market Newswire · 2026/9/24
• Rating change
  Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
  TipRanks · 2026/8/12
• Rating change
  Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $65
  Market Newswire · 2026/6/25
• Rating change
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $68 to $85
  Market Newswire · 2026/8/6
• Rating change
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $62 to $85
  Market Newswire · 2026/8/5
• Rating change
  CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $70
  Market Newswire · 2026/8/12
• H.C. Wainwright Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $67
  Market Newswire · 2026/10/3
• Rating change
  Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Maintains Target Price $62
  Market Newswire · 2026/8/10
• Rating change
  Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/7/22
• Rating change
  BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $64
  Market Newswire · 2026/7/22

Headlines are aggregated automatically and are not independently verified or edited by our team.